Hepatic steatosis is the earliest stage of fatty liver disease, sitting at the very beginning of a progression that can advance through inflammation, scarring, and eventually cirrhosis. On the fibrosis scale used to measure liver damage, simple steatosis corresponds to F0, meaning no scarring is present yet. This is the most reversible point in the spectrum, and for the majority of people, the disease never progresses beyond it.
Where Steatosis Falls in the Disease Spectrum
Fatty liver disease progresses through a sequence of stages, each defined by increasing damage to the liver. Hepatic steatosis is the first. It means fat has accumulated in your liver cells, but there’s little or no inflammation and no significant cell damage. Most people at this stage have a fully functioning liver.
If the condition worsens, the next stage involves inflammation and liver cell injury. This was previously called NASH (nonalcoholic steatohepatitis) and is now referred to as MASH (metabolic dysfunction-associated steatohepatitis) under updated terminology adopted in 2023. From there, the liver can develop fibrosis, which is scarring measured on a five-point scale:
- F0: No scarring (simple steatosis lives here)
- F1: Mild scarring
- F2: Moderate scarring
- F3: Advanced scarring
- F4: Cirrhosis
This fibrosis stage is the single most important factor in determining long-term outcomes and survival. Simple steatosis at F0 carries the best prognosis of any point on this scale.
How Steatosis Is Defined and Graded
A liver is clinically considered steatotic when 5% or more of its cells contain visible fat deposits. Below that threshold, fat content is considered normal. Once you cross that line, steatosis itself is graded by severity:
- Grade 1 (mild): 5% to 33% of liver cells contain fat
- Grade 2 (moderate): 34% to 66%
- Grade 3 (severe): 67% or more
These grades describe how much fat is in the liver, but they don’t automatically predict whether you’ll develop inflammation or scarring. Someone with grade 3 steatosis could remain at F0 fibrosis indefinitely, while someone with grade 1 could, in rare cases, progress if other metabolic risk factors are present.
On MRI-based imaging, the 5% threshold used in biopsy translates to a proton density fat fraction of roughly 6% to 6.4%. If you’ve had a FibroScan, the device reports a CAP (controlled attenuation parameter) score measured in dB/m. Scores above 290 dB/m suggest advanced fat accumulation, though FibroScan is better at confirming that steatosis exists than at pinpointing its exact grade.
Why It Usually Causes No Symptoms
Hepatic steatosis is considered a “silent” condition. Most people have no symptoms at all and discover it incidentally through blood work or an imaging scan done for another reason. When symptoms do appear, they’re typically vague: fatigue or a dull ache in the upper right side of the abdomen. Even later stages of fatty liver disease, including cirrhosis, can be surprisingly symptom-free in some people. This is why the disease often goes undetected for years.
How Common It Is
Fatty liver disease is remarkably widespread. A 2025 meta-analysis covering more than 11 million people found that steatotic liver disease affects about 37.5% of the global population, making it the most common liver condition in the world. The metabolic subtype (formerly called NAFLD, now MASLD) accounts for 33.6% of the general population on its own.
Prevalence climbs sharply in people with metabolic conditions. Among those with type 2 diabetes, roughly 70% have fatty liver disease. The figure is nearly identical, around 71%, in people who are overweight or obese. These numbers explain why hepatic steatosis is now viewed less as a standalone liver problem and more as a feature of broader metabolic dysfunction.
What Drives Progression to Later Stages
Most people with simple steatosis will never develop significant liver damage. The risk of progressing to inflammation and scarring rises substantially, however, when certain metabolic factors are present. Insulin resistance is the most consistently identified driver. Central obesity (fat concentrated around the midsection), abnormal cholesterol and triglyceride levels, elevated uric acid, and type 2 diabetes or prediabetes all increase the likelihood of moving beyond steatosis.
Diet plays a measurable role as well. High fructose intake correlates with higher levels of liver enzymes and worsening insulin resistance, independent of body weight. This means that even people who aren’t significantly overweight can see their liver condition worsen if their metabolic health deteriorates.
Reversing Steatosis Through Lifestyle Changes
The good news about catching fatty liver disease at the steatosis stage is that it responds well to intervention. Weight loss of 7% to 10% of total body weight is the most effective treatment and can improve not just fat accumulation but also inflammation and early scarring if any has begun. For someone weighing 200 pounds, that translates to losing 14 to 20 pounds.
Exercise alone can reduce liver fat and improve insulin sensitivity within about eight weeks, even before significant weight loss occurs. Combining dietary changes with regular physical activity produces the strongest results, with studies showing body weight reductions of 4% to 11% and measurable improvements in liver enzymes. Longer interventions, beyond 24 weeks, tend to produce more durable results than short-term programs.
Improvements in liver fat and enzyme levels have been documented in both obese and non-obese patients after a year of sustained lifestyle changes. Because steatosis sits at F0 with no scarring, it represents the point where the liver can most completely return to normal. The further disease progresses along the fibrosis scale, the harder reversal becomes.
Updated Terminology
If you’ve seen the terms NAFLD and MASLD used interchangeably, here’s why. In 2023, a global consensus of medical societies renamed nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD). The new name reflects the understanding that this condition is driven by metabolic factors, not simply the absence of alcohol use. Under the updated definition, a diagnosis of MASLD requires evidence of liver fat plus at least one of five cardiometabolic risk factors, such as elevated blood sugar, high blood pressure, or abnormal lipid levels. Simple hepatic steatosis remains the earliest presentation within this reclassified framework.